Bambusa Therapeutics, Inc. (NASDAQ:BBTX – Get Free Report) major shareholder Salvia Investment Gmbh purchased 375,000 shares of the company’s stock in a transaction on Monday, November 2nd. The stock was purchased at an average price of $16.00 per share, with a total value of $6,000,000.00. Following the completion of the transaction, the insider owned 9,264,301 shares of the company’s stock, valued at approximately $148,228,816. This trade represents a 4.22% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Bambusa Therapeutics Price Performance
Shares of NASDAQ BBTX opened at $16.00 on Wednesday. Bambusa Therapeutics, Inc. has a 1 year low of $13.60 and a 1 year high of $17.42.
Recommended Stories
- Five stocks we like better than Bambusa Therapeutics
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Bambusa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bambusa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
